MicroRNA‑424 serves an anti‑oncogenic role by targeting cyclin‑dependent kinase 1 in breast cancer cells

Xie,Dan; Song,Hongming; Wu,Tianqi; Li,Dengfeng; Hua,Kaiyao; Xu,Hui; Zhao,Bingkun; Wu,Chenyang; Hu,Jiashu; Ji,Changle; Deng,Yijun; Fang,Lin

doi:10.3892/or.2018.6741

MicroRNA‑424 serves an anti‑oncogenic role by targeting cyclin‑dependent kinase 1 in breast cancer cells

Authors:
- Dan Xie
- Hongming Song
- Tianqi Wu
- Dengfeng Li
- Kaiyao Hua
- Hui Xu
- Bingkun Zhao
- Chenyang Wu
- Jiashu Hu
- Changle Ji
- Yijun Deng
- Lin Fang
View Affiliations

Affiliations: Department of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital, Tongji University, School of Medicine, Shanghai 200072, P.R. China, Department of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital, Tongji University, School of Medicine, Shanghai 200072, P.R. China
Published online on: September 27, 2018 https://doi.org/10.3892/or.2018.6741
Pages: 3416-3426
Copyright: © Xie et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to define the function of microRNA‑424‑5p (miR‑424) in breast cancer cells. The present study investigated the level and the potential function of miR‑424 in breast cancer by reverse transcription‑quantitative polymerase chain reaction assays. miR‑424 expression was decreased in the majority of human breast cancer specimens and cell lines used in the present study. The MTT assay, plate colony formation assay and flow cytometry analyses were used to characterize the function of miR‑424 in two types of breast cancer cell lines. Upregulation of miR‑424 inhibited cellular proliferation and regulated the cell cycle by arresting cells in the G2/M cell phase. The dual‑luciferase reporter assay was used to confirm the direct association between miR‑424 and cyclin‑dependent kinase 1 (CDK1). Silencing of CDK1 expression by CDK1 short interfering RNA also significantly suppressed cell proliferation and arrested cells in the G2/M cell phase. The results of the present study indicated that miR‑424 can suppress cell proliferation and arrest cells in G2/M cell phase by negatively regulating CDK1 mRNA in human breast cancer, possibly through the Hippo pathway and the extracellular signal‑regulated kinase pathway. The results of the present study provided novel evidence for the role of miR‑424 in breast cancer.

View Figures

View References

1	Bombonati A and Sgroi DC: The molecular pathology of breast cancer progression. J PATHOL. 223:307–31. 2011. View Article : Google Scholar : PubMed/NCBI
2	Yates LA, Norbury CJ and Gilbert RJ: The long and short of microRNA. Cell. 153:516–519. 2013. View Article : Google Scholar : PubMed/NCBI
3	Esteller M: Non-coding RNAs in human disease. Nat Rev Genet. 12:861–874. 2011. View Article : Google Scholar : PubMed/NCBI
4	Xiao M, Li J, Li W, Wang Y, Wu F, Xi Y, Zhang L, Ding C, Luo H, Li Y, et al: MicroRNAs activate gene transcription epigenetically as an enhancer trigger. RNA Biol. 14:1326–1334. 2017. View Article : Google Scholar : PubMed/NCBI
5	Friedman RC, Farh KK, Burge CB and Bartel DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19:92–105. 2009. View Article : Google Scholar : PubMed/NCBI
6	Dvinge H, Git A, Graf S, Salmon-Divon M, Curtis C, Sottoriva A, Zhao Y, Hirst M, Armisen J, Miska EA, et al: The shaping and functional consequences of the microRNA landscape in breast cancer. Nature. 497:378–382. 2013. View Article : Google Scholar : PubMed/NCBI
7	Cekaite L, Eide PW, Lind GE, Skotheim RI and Lothe RA: MicroRNAs as growth regulators, their function and biomarker status in colorectal cancer. Oncotarget. 7:6476–6505. 2016. View Article : Google Scholar : PubMed/NCBI
8	Wu CT, Lin WY, Chang YH, Lin PY, Chen WC and Chen MF: DNMT1-dependent suppression of microRNA424 regulates tumor progression in human bladder cancer. Oncotarget. 6:24119–24131. 2015.PubMed/NCBI
9	Zhou Y, An Q, Guo RX, Qiao YH, Li LX, Zhang XY and Zhao XL: miR424-5p functions as an anti-oncogene in cesrvical cancer cell growth by targeting KDM5B via the Notch signaling pathway. Life Sci. 171:9–15. 2017. View Article : Google Scholar : PubMed/NCBI
10	Zhang J, Kong X, Li J, Luo Q, Li X, Shen L, Chen L and Fang L: miR-96 promotes tumor proliferation and invasion by targeting RECK in breast cancer. Oncol Rep. 31:1357–1363. 2014. View Article : Google Scholar : PubMed/NCBI
11	Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
12	Rahmani-Nezhad S, Safavi M, Pordeli M, Ardestani SK, Khosravani L, Pourshojaei Y, Mahdavi M, Emami S, Foroumadi A and Shafiee A: Synthesis, in vitro cytotoxicity and apoptosis inducing study of 2-aryl-3-nitro-2H-chromene derivatives as potent anti-breast cancer agents. Eur J Med Chem. 86:562–569. 2014. View Article : Google Scholar : PubMed/NCBI
13	Tirona MT, Sehgal R and Ballester O: Prevention of breast cancer (part I): Epidemiology, risk factors, and risk assessment tools. Cancer Invest. 28:743–750. 2010. View Article : Google Scholar : PubMed/NCBI
14	Jahagirdar D, Purohit S, Jain A and Sharma NK: Export of microRNAs: A bridge between breast carcinoma and their neighboring cells. Front Oncol. 6:1472016. View Article : Google Scholar : PubMed/NCBI
15	Luo Q, Li X, Li J, Kong X, Zhang J, Chen L, Huang Y and Fang L: MiR-15a is underexpressed and inhibits the cell cycle by targeting CCNE1 in breast cancer. Int J Oncol. 43:1212–128. 2013. View Article : Google Scholar : PubMed/NCBI
16	Li J, Kong X, Zhang J, Luo Q, Li X and Fang L: Correction: MiRNA-26b inhibits proliferation by targeting PTGS2 in breast cancer. Cancer Cell Int. 13:172013. View Article : Google Scholar : PubMed/NCBI
17	Braza-Boils A, Mari-Alexandre J, Gilabert J, Sanchez-Izquierdo D, Espana F, Estelles A and Gilabert-Estellés J: MicroRNA expression profile in endometriosis: Its relation to angiogenesis and fibrinolytic factors. Hum Reprod. 29:978–988. 2014. View Article : Google Scholar : PubMed/NCBI
18	Gambari R, Brognara E, Spandidos DA and Fabbri E: Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: New trends in the development of miRNA therapeutic strategies in oncology (Review). Int J Oncol. 49:5–32. 2016. View Article : Google Scholar : PubMed/NCBI
19	Jahagirdar D, Purohit S, Jain A and Sharma NK: Export of microRNAs: A bridge between breast carcinoma and their neighboring cells. Front Oncol. 6:1472016. View Article : Google Scholar : PubMed/NCBI
20	Bertoli G, Cava C and Castiglioni I: The potential of miRNAs for diagnosis, treatment and monitoring of breast cancer. Scand J Clin Lab Invest Suppl. 245:S34–S39. 2016. View Article : Google Scholar : PubMed/NCBI
21	Bertoli G, Cava C and Castiglioni I: MicroRNAs: New biomarkers for deiagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. Theranostics. 5:1122–1143. 2015. View Article : Google Scholar : PubMed/NCBI
22	Cava C, Bertoli G and Castiglioni I: Integrating genetics and epigenetics in breast cancer: Biological insights, experimental, computational methods and therapeutic potential. BMC Syst Biol. 9:622015. View Article : Google Scholar : PubMed/NCBI
23	Lee H, Kim KR, Cho NH, Hong SR, Jeong H, Kwon SY, Park KH, An HJ, Kim TH, Kim I, et al: MicroRNA expression profiling and Notch1 and Notch2 expression in minimal deviation adenocarcinoma of uterine cervix. World J Surg Oncol. 12:3342014. View Article : Google Scholar : PubMed/NCBI
24	Nurse P, Masui Y and Hartwell L: Understanding the cell cycle. Nat Med. 4:1103–1116. 1998. View Article : Google Scholar : PubMed/NCBI
25	Malumbres M and Barbacid M: Cell cycle, CDKs and cancer: A changing paradigm. Nat Rev Cancer. 9:153–1566. 2009. View Article : Google Scholar : PubMed/NCBI
26	Lapenna S and Giordano A: Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 8:547–566. 2009. View Article : Google Scholar : PubMed/NCBI
27	Asghar U, Witkiewicz AK, Turner NC and Knudsen ES: The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 14:130–146. 2015. View Article : Google Scholar : PubMed/NCBI
28	Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, et al: The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole vs letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. Lancet Oncol. 16:25–35. 2015. View Article : Google Scholar : PubMed/NCBI
29	Sherr CJ, Beach D and Shapiro GI: Targeting CDK4 and CDK6: From discovery to therapy. Cancer Discov. 6:353–367. 2016. View Article : Google Scholar : PubMed/NCBI
30	Santamaria D, Barriere C, Cerqueira A, Hunt S, Tardy C, Newton K, Cáceres JF, Dubus P, Malumbres M and Barbacid M: Cdk1 is sufficient to drive the mammalian cell cycle. Nature. 448:811–815. 2007. View Article : Google Scholar : PubMed/NCBI
31	Li J, Li X, Kong X, Luo Q, Zhang J and Fang L: MiRNA-26b inhibits cellular proliferation by targeting CDK8 in breast cancer. Int J Clin Exp Med. 7:558–565. 2014.PubMed/NCBI
32	Li XY, Luo QF, Wei CK, Li DF, Li J and Fang L: MiRNA-107 inhibits proliferation and migration by targeting CDK8 in breast cancer. Int J Clin Exp Med. 7:32–40. 2014.PubMed/NCBI
33	Li XY, Luo QF, Wei CK, Li DF and Fang L: siRNA-mediated silencing of CDK8 inhibits proliferation and growth in breast cancer cells. Int J Clin Exp Pathol. 7:92–100. 2013.PubMed/NCBI
34	Hua K, Jin J, Zhang H, Zhao B, Wu C, Xu H and Fang L: MicroRNA-7 inhibits proliferation, migration and invasion of thyroid papillary cancer cells via targeting CKS2. Int J Oncol. 49:1531–1540. 2016. View Article : Google Scholar : PubMed/NCBI
35	Shi P, Feng J and Chen C: Hippo pathway in mammary gland development and breast cancer. Acta Biochim Biophys Sin. 47:53–59. 2015. View Article : Google Scholar : PubMed/NCBI
36	McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, et al: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 1773:1263–1284. 2007. View Article : Google Scholar : PubMed/NCBI
37	Cargnello M and Roux PP: Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev. 75:50–83. 2011. View Article : Google Scholar : PubMed/NCBI
38	Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, Franklin RA and McCubrey JA: Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: Potential targeting for therapeutic intervention. Leukemia. 17:1263–1293. 2003. View Article : Google Scholar : PubMed/NCBI